Spiropyrrolidine derived antiviral agents
Inventors
Wang, Guoqiang • Shen, Ruichao • He, Yong • Ma, Jun • Xing, Xuechao • Cao, Hui • Gao, Xuri • Peng, Xiaowen • Long, Jiang • Li, Wei • Zhang, Jiajun • Panarese, Joseph D. • Kenton, Nathaniel Thomas • Bartlett, Samuel • Or, Yat Sun
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
Core Innovation
The claimed subject matter provides spiropyrrolidine-derived compounds represented by Formula (Ia) or Formula (I), or pharmaceutically acceptable salts thereof, that inhibit coronavirus 3C-like protease. Formula (Ia) defines structural variables A, B, and X, alongside specified alternatives for substituents R1–R4 and R11–R16. Embodiments encompass spiro[indoline-3,3′-pyrrolidine] derivatives, bicyclic lactams, and peptidomimetic compounds with varied aryl, heteroaryl, indole, and nitrile substitutions.
Analytical characterization via mass spectrometry and nuclear magnetic resonance confirms the synthesized compound embodiments; [procedural detail omitted for safety]. Reported biological evaluation demonstrates SARS-CoV-2 3CL protease inhibition and antiviral activity against human coronavirus 229E. The disclosure further provides pharmaceutical compositions and treatment methods directed to coronavirus infection, including SARS-CoV-2, with optional combination therapy.
Claims Coverage
The claims identify two independent claims covering two inventive features directed to a structurally defined compound genus of Formula (Ia) and an enumerated set of compounds, each including pharmaceutically acceptable salts.
Formula (Ia) compounds and salts
Claim 1 covers a compound represented by Formula (Ia), or a pharmaceutically acceptable salt thereof, wherein structural variables A, B, and X, and substituent groups R1–R4 and R11–R16 are defined by specified alternatives, including optionally substituted aryl or heteroaryl groups and carbocyclic or heterocyclic ring-forming options.
Enumerated compounds and salts
Claim 9 covers a compound selected from an enumerated set of compounds, specifically compounds 1 through 552, or a pharmaceutically acceptable salt thereof.
The independent claims cover the Formula (Ia) compound genus and the enumerated set of compounds, each including pharmaceutically acceptable salts. Dependent claims further recite compound subfamilies, pharmaceutical compositions comprising a carrier or excipient, and methods of treating coronavirus infection, including SARS-CoV-2.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Pharmaceutical compositions comprising a compound of Formula (Ia) or an enumerated compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient, including combination therapy.
Treatment or prevention of viral infections, particularly coronavirus infection including SARS-CoV-2, by administering a therapeutically effective amount of a claimed compound or pharmaceutically acceptable salt to a subject in need.
Inhibition of SARS-CoV-2 3CL protease and antiviral activity against human coronavirus 229E, providing coronavirus protease inhibitors and antiviral candidates.
Interested in licensing this patent?